Statistics in Biopharmaceutical Research

Papers
(The H4-Index of Statistics in Biopharmaceutical Research is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Predicting Probability of Success for Phase III Trials via Propensity-Score-Based External Data Borrowing32
U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs21
DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials19
Treatment Selection at Interim Analysis Based on a Correlated Early Endpoint in Adaptive Two-Stage Trials with a Primary Endpoint Based on Count Data14
Joint Analysis of Longitudinal Ordinal Categorical Item Response Data and Survival Times with Cure Fraction12
Some Multiplicity Adjustment Procedures for Clinical Trials with Sequential Design and Multiple Endpoints11
A Basket Trial Design Based on Power Priors11
We Need Subject Matter Expertise to Choose and Identify Causal Estimands: Comment on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”11
Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective10
Consistency Based Multiplicity Adjustment Approach—Multiple Doses in Phase III Studies10
Modified Simon’s Two-Stage Design for Phase IIA Clinical Trials in Oncology—Dynamic Monitoring and More Flexibility10
0.051074028015137